A456570 Stock Overview
Engages in researching and developing of an ultrasound-guided therapy technology for genetic therapy and drug delivery systems. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
IMGT Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩11,980.00 |
| 52 Week High | ₩26,500.00 |
| 52 Week Low | ₩5,900.00 |
| Beta | 0 |
| 11 Month Change | 0.34% |
| 3 Month Change | -6.41% |
| 1 Year Change | 85.74% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -25.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| A456570 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0.3% | -1.5% | 0.9% |
| 1Y | 85.7% | 23.1% | -3.4% |
Return vs Industry: A456570 exceeded the KR Biotechs industry which returned 23.1% over the past year.
Return vs Market: A456570 exceeded the KR Market which returned -3.4% over the past year.
Price Volatility
| A456570 volatility | |
|---|---|
| A456570 Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A456570 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A456570's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Hakjong Lee | www.nanoimgt.com |
IMGT Co.,Ltd. engages in researching and developing of an ultrasound-guided therapy technology for genetic therapy and drug delivery systems. It develops IMGT-LPS, a technology that injects ultrasound-sensitive nanoparticles in the form of liposome-wrapped pharmacological substances into the body and releases drugs by irradiating ultrasound to the target area(tumor); IMGT-EMB, a nanoparticle for chemoembolization of liver cancer; IMGT-TSD, a targeted sonodynamic therapy that induces immune boosting mechanism by applying ultrasonic stimulation to the cancerous area; and IMGT-FUS, a device for non-invasive treatment.
IMGT Co.,Ltd. Fundamentals Summary
| A456570 fundamental statistics | |
|---|---|
| Market cap | ₩59.00b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A456570 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A456570 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A456570 perform over the long term?
See historical performance and comparison